


5- - -
4- -1- 2- - -D- - -1 3 5- -2 1H -



$C_8H_{12}N_4O_4$

228.21

IPSS

-1

-2

MDS

MDS

FAB

50mg

MDS

3

5

4

4

3

15mg/m² 3 8 1 3
9 6 1
45mg/m² 135mg/m²

5

20mg/m² 1 1 5
5 4 1
20mg/m² 100mg/m²

MDS

- 5

• 3
1 3 4
3
3

MDS

<1000/ μ L


500/ μ L

MDS

<25000/ μ L

• 3
•
•

6 6



10

MDS

	10 mL	USP	mL	5.0 mg
pH	6.7~7.3	0.9%	5%	
	0.15~1.0mg/mL		15	
2°C~8°C		2°C~8°C	4	
/				
3	5			
	3	N=66	N=98	N=99
N=83	N=81			1

D-0007

≥1%

-

MDSIII	D-0007	83			
15mg/m ²		8	1	3	6
3 0~9	1			5%	

1 III MDS ≥5%

	N=83 %	N=81 %
*	75 90	58 72
	74 89	64 79
NOS	68 82	60 74
*	24 29	5 6
NOS	23 28	11 14
	10 12	6 7
	4 5	1 1
NOS	5 6	0 0
	5 6	0 0
	35 42	13 16
	29 35	11 14
NOS	28 34	13 16
NOS	21 25	7 9
NOS	12 14	5 6
	11 13	4 5
	10 12	5 6
	10 12	1 1
	8 10	2 2
	7 8	5 6
	7 8	3 4
	6 7	3 4

	6 7	2 2
	5 6	2 2
NOS	5 6	1 1
	4 5	3 4
	4 5	1 1
	4 5	1 1
	4 5	0 0
	4 5	0 0
	44 53	23 28
	21 25	13 16
	18 22	14 17
NOS	15 18	5 6
NOS	11 13	5 6
	10 12	3 4
NOS	9 11	0 0
	7 8	3 4
	6 7	3 4
	5 6	3 4
	4 5	1 1
NOS	4 5	1 1
	4 5	1 1
	4 5	0 0
	4 5	0 0
	12 14	4 5
NOS*	18 22	11 14
	10 12	6 7
NOS	8 10	1 1
	7 8	0 0
NOS*	6 7	1 1
	6 7	0 0
	5 6	2 2
NOS	4 5	2 2
	4 5	0 0
	6 7	3 4
NOS	4 5	1 1
NOS	13 16	9 11
NOS	9 11	7 9
AST	8 10	7 9
	8 10	1 1
	7 8	5 6
	6 7	0 0
	5 6	1 1
	5 6	1 1
	4 5	3 4
	4 5	1 1
	4 5	1 1

NOS	27 33	16 20
	20 24	14 17
	20 24	6 7
	18 22	10 12
	16 19	13 16
NOS	13 16	12 15
	13 16	8 10
	11 13	3 4
	5 6	4 5
	17 20	8 10
	16 19	8 10
	14 17	5 6
	6 7	1 1
	5 6	0 0
	4 5	1 1
	23 28	11 14
	15 18	10 12
	9 11	1 1
	23 28	11 14
	10 12	3 4
	9 11	8 10
	5 6	3 4
	4 5	1 1
	33 40	25 31
	13 16	6 7
	12 14	1 1
	8 10	7 9
	8 10	4 5
	7 8	2 2
	4 5	2 2
	18 22	12 15
NOS	16 19	7 9
	12 14	5 6
NOS	9 11	3 4
	9 11	2 2
	7 8	1 1
NOS	5 6	1 1
	5 6	0 0
	32 39	13 16
	19 23	10 12
NOS	5 6	4 5
NOS	4 5	3 4
NOS		

*

D-0007		3 4			87%
	85%		23%		22%
			6		

83		8			81
1					

2		5%			
---	--	----	--	--	--

2		≥5%			§
---	--	-----	--	--	---

	N=99	%
	31	31
*	20	20
	6	6
*	38	38
*	5	5
	5	5
*	27	27
	5	5
	8	8
	6	6
	14	14
	6	6
	30	30
	28	28
	10	10
	5	5
	5	5
	40	40
	5	5
	11	11
	6	6
	16	16
	15	15

	6 6
	16 16
	46 46
	9 9
	5 5
	27 27
	5 5
	36 36
	9 9
	6 6
*	20 20
	6 6
	8 8
	5 5
	10 10
*	7 7
	9 9
	6 6
	5 5
	9 9
	23 23
	8 8
	8 8
	6 6
	12 12
	5 5
	17 17
	18 18
	6 6
	7 7
	5 5
	5 5
	9 9
	18 18
	21 21
	23 23
	9 9
	8 8
	9 9
	14 14
	27 27
	29 29
	13 13

	8 8
	5 5
	5 5
	8 8
	9 9
	5 5
	5 5
	12 12
	9 9
	11 11
	5 5
	6 6
	11 11
*	

MDS 65

1 2

-
-
-
-
-
-
-
-
-
-

-

-
-
-
-
-
-
-

II

D-0007

2011 8

3 MedDRA

TEAE ≥5% MYE-3002 -

MedDRA	3 (N=34)	5 (N=97)	(N=131)
	(%)	(%)	(%)
(TEAE)	32(94.1)	65(67.0)	97(74.0)
	30(88.2)	58(59.8)	88(67.2)
	22(64.7)	40(41.2)	62(47.3)
*	21(61.8)	32(33.0)	53(40.5)
	16(47.1)	27(27.8)	43(32.8)
	14(41.2)	19(19.6)	33(25.2)

MedDRA	3 (N=34)	5 (N=97)	(N=131)
	(%)	(%)	(%)
	11(32.4)	11(11.3)	22(16.8)
	4(11.8)	7(7.2)	11(8.4)
	4(11.8)	4(4.1)	8(6.1)
	2(5.9)	5(5.2)	7(5.3)
	1(2.9)	5(5.2)	6(4.6)
	3(8.8)	1(1.0)	4(3.1)
	22(64.7)	42(43.3)	64(48.9)
	20(58.8)	37(38.1)	57(43.5)
	4(11.8)	8(8.2)	12(9.2)
	20(58.8)	39(40.2)	59(45.0)
	7(20.6)	16(16.5)	23(17.6)
	5(14.7)	18(18.6)	23(17.6)
*	5(14.7)	6(6.2)	11(8.4)
*	6(17.6)	2(2.1)	8(6.1)
	3(8.8)	1(1.0)	4(3.1)
	2(5.9)	1(1.0)	3(2.3)
*	2(5.9)	1(1.0)	3(2.3)
	2(5.9)	0	2(1.5)
	2(5.9)	0	2(1.5)
	23(67.6)	35(36.1)	58(44.3)
	6(17.6)	9(9.3)	15(11.5)
	6(17.6)	8(8.2)	14(10.7)
	6(17.6)	8(8.2)	14(10.7)
	9(26.5)	5(5.2)	14(10.7)
	2(5.9)	5(5.2)	7(5.3)
	0	7(7.2)	7(5.3)
	3(8.8)	4(4.1)	7(5.3)
	3(8.8)	1(1.0)	4(3.1)
	2(5.9)	2(2.1)	4(3.1)
	2(5.9)	1(1.0)	3(2.3)
	3(8.8)	0	3(2.3)
	2(5.9)	1(1.0)	3(2.3)
	12(35.3)	22(22.7)	34(26.0)
	6(17.6)	8(8.2)	14(10.7)
	4(11.8)	7(7.2)	11(8.4)
	2(5.9)	1(1.0)	3(2.3)
	8(23.5)	22(22.7)	30(22.9)
	5(14.7)	5(5.2)	10(7.6)
	0	9(9.3)	9(6.9)
	2(5.9)	3(3.1)	5(3.8)
	7(20.6)	20(20.6)	27(20.6)
	7(20.6)	14(14.4)	21(16.0)
	1(2.9)	8(8.2)	9(6.9)
	0	8(8.2)	8(6.1)
	2(5.9)	4(4.1)	6(4.6)
	7(20.6)	19(19.6)	26(19.8)
	3(8.8)	12(12.4)	15(11.5)
*	4(11.8)	3(3.1)	7(5.3)

MedDRA	3 (N=34)	5 (N=97)	(N=131)
	(%)	(%)	(%)
	7(20.6)	9(9.3)	16(12.2)
	3(8.8)	3(3.1)	6(4.6)
	3(8.8)	2(2.1)	5(3.8)
	7(20.6)	7(7.2)	14(10.7)
	2(5.9)	2(2.1)	4(3.1)
	2(5.9)	1(1.0)	3(2.3)
	2(5.9)	0	2(1.5)
	5(14.7)	7(7.2)	12(9.2)
	3(8.8)	6(6.2)	9(6.9)
	4(11.8)	6(6.2)	10(7.6)
	3(8.8)	3(3.1)	6(4.6)
	1(2.9)	8(8.2)	9(6.9)
	2(5.9)	3(3.1)	5(3.8)
	2(5.9)	3(3.1)	5(3.8)
	2(5.9)	1(1.0)	3(2.3)
	2(5.9)	0	2(1.5)
	2(5.9)	0	2(1.5)
	2(5.9)	0	2(1.5)
MedDRA=	N=	TEAE=	
*			

<

<

<

<

4

1

/

1

2

MDS

[CrCl]<30ml/min

3

MDS

III	83	61	65	21
75				

<1%

20

CYP450

CYP

C_{max}

P-gp

P-gp

20

170

MDS

[FAB] MDS

[IPSS]

-1 -2 89 + 83

81 SC AML

12 AML 9

3 SC ITT

5

5 ITT

	N=89	N=81
y ±SD IQR ~	69±10 70 65~76 31~85	67±10 70 62~74 30~82
n %	59 66 30 34	57 70 24 30
n %	83 93 4 4 2 2	76 94 2 2 3 4

n %	23 26 66 74	27 33 54 67
n %	69 78 20 22	62 77 19 23
IPSS n %		
-1	28 31	24 30
-2	38 43 23 26	36 44 21 26
FAB n %		
RA	12 13	12 15
RARS	7 8	4 5
RAEB	47 53	43 53
RAEB-t	17 19	14 17
CMML	6 7	8 10

15mg/m² 8 3 3
6 1 + AML
MDS IWG
6 III *

CR	<5%
	>11g/dL
PR	FAB MDS
	CR
*Cheson BD Bennett JM et al. MDS Blood.2000 96 3671-3674.	

ITT CR+PR 17% SC 0% p<0.001 7
21% 12/56 MDS
288 116~388
93 55~272 1 4
13% PR

8 SC 7%

AML

AML

8 9

7 ITT

	N=89	N=81
CR+PR	15 17% **	0 0%
CR	8 9%	0 0%
PR	7 8%	0 0%
CR+PR	93 55~272	NA
CR+PR	288 116~388	NA
** vs p <0.001		

CR PR

AML

8

AML

	N 89	N 81	p †
~			
† Wilcoxon Log-rank			

9

AML

			p †
IPSS -1 n	N 28	N 24	
IPSS -2 n	N 38	N 36	
IPSS n	N 23	N 21	
IPSS -2 n	N 61	N 57	

n	N 30	N 24	
n	N 59	N 57	
< 65 n	N 23	N 30	
% 95%CI			
65~74 n	N 42	N 35	
% 95%CI			
≥ 75 n	N 24	N 16	
% 95%CI			
FAB RA n	N 12	N 12	
% 95%CI			
FAB RARS n	N 7	N 4	
FAB RAEB n	N 47	N 43	
FAB RAEB-t n	N 17	N 14	
FAB CMML n	N 6	N 8	
MDS n	N 27	N 19	
MDS n	N 62	N 62	
n	N 77	N 70	

	n	N 12	N 11
†	p		
	Wilcoxon		
	Log-rank		
NC			

FAB MDS

99 IPSS -1 -2

5 4 1~5 1 20mg/m² 1

10 11

10

ITT

		N=99
y		71±9
±SD	~	72 34~87
n %		71 72
		28 28
n %		86 87
		6 6
		4 4
		3 3
MDS	1	444±626
±SD	~	154 7~3079
MDS	n %	27 27
		72 73
n %		33 33
		66 67
n %		84 85
		15 15
IPSS	n %	1 1
	1	52 53

-2		23	23
		23	23
FAB	n	%	
RA	20	20	
RARS	17	17	
RAEB	45	45	
RAEB-t	6	6	
CMML	11	11	

11 ITT *

	N=99
CR+PR	16 16%
CR	15 15%
PR	1 1%
CR+PR	162 50~267
CR+PR	443 72~722+
+ * Cheson BD, Bennett JM, et al. Report of an International Working Group to Standardize Response Criteria for MDS. <i>Blood</i> . 2000; 96:3671-3674	

MYE-3002

MDS				132	18		MDS
			[FAB]	MDS			[IPSS]
-1	-2			1:1		3	5
		3		ITT		30	
5							
• 3			3	15mg/m ²		8	1
			1				3
• 5			1	20mg/m ²		1	5
			1				1
4							
				+		+	
		53.9		59%		MDS	MDS
		62%				RAEB	IPSS
41%	-1	43%	-2	16%		69%	ECOG
							FAB
							1

2011 8 3 23%
 + + 3 26% 5
 22% + + 40% 3
 44% 5 38% 80% 3 83%
 5 78%

DNA DNA DNA
 DNA DNA
 DNA DNA

L5178Y 1ac-I DNA 1ac-I

0.3%~1% 3 7 0.15 0.3 0.45mg/m²
 2 2
 8 9 10 11 0.9 3mg/m²
 2% 7% 3mg/m²
 3mg/m²
 9~12 2.4 3.6 6.0mg/m²
 5% 8% 13% 9
 10 3.6mg/m²
 6.0mg/m²

3.6mg/m²

6.0mg/m²

10

3mg/m²

7%

3

5

36% 0%

3	5	20mg/m ²	1	5	4	DACO-
017(n=11)	DACO-020(n=11)	DACO-016(n=23)	1	3	15mg/m ²	3
8	1	3	6	DACO-018(n=12)		MDS
AML			5	1		5
			100mg/m ²	3	1	
					135mg/m ²	

1

1

5

3

3

70kg

1.73m²

12

12

5

3

AUC=	-	CL=	C _{max} =	t _{1/2} =
	V _{d_{ss}} =			

0.5

<1%

V_{d_{ss}}

DNA

P450

2.4%

4%

P-gp

>200L/h

CV

50%

¹⁴C-

90%

4%

4

40~87

70

MYE-3002 24 MDS

15mg/m² 8 7 5

3

20mg/m² 17 JPN-MDS-101 8 MDS

15mg/m² 5 3 20mg/m² 5 5

MYE-3002 JPN-MDS-101

CYP

25°C

1 /

36

JX20130282

HJ20181217

BSP Pharmaceuticals S.p.A

Via Appia km. 65, 561, 04013 Latina Scalo (LT), Italy